Royal London Hospital
Royal London Hospital
London, United Kingdom14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07533006 | |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06721013 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohns Disease | Recruiting | Phase 3 | 2026-09-28 | NCT06819891 | |
| ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis | CNS demyelinating autoimmune disease, Charcot-Marie-Tooth disease type 1F, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-08 | NCT04695080 | |
| EEG Monitoring for Refractory Status Epilepticus | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Status Epilepticus, nervous system disorder, visual epilepsy | Recruiting | Not applicable | 2026-09-08 | NCT04170491 | |
| A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) | Digestive System Diseases, Intestinal Failure, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, short bowel syndrome | Recruiting | Phase 3 | 2026-08-04 | NCT07742735 | |
| Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Steatohepatitis, fatty liver disease, liver disorder | Recruiting | Not applicable | 2026-07-31 | NCT07013916 | |
| Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Recruiting | Phase 2 / Phase 3 | 2026-04-22 | NCT07080385 | |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-03-04 | NCT04302870 | |
| Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) | CNS demyelinating autoimmune disease, Charcot-Marie-Tooth disease type 1F, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 2 | 2026-01-07 | NCT05418010 | |
| MuScle WastIng and DysphaGia iN CriticAlly IlL Patients (SIGNAL) | Atrophy, Critical Illness, Deglutition Disorders, Digestive System Diseases, Disease Attributes, Neurologic Manifestations, Neuromuscular Manifestations, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Signs and Symptoms, digestive system disorder, esophageal disorder, muscular atrophy, nervous system disorder, otorhinolaryngologic disease | Recruiting | Not stated | 2025-11-18 | NCT07076524 | |
| Electroporation for Cancer Treatment Real World Registry | Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, digestive system disorder, digestive system neoplasm, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2025-01-29 | NCT04929912 |